Rule out Crohn's disease and ulcerative colitis

Gold serum separator (SST) tube

Immediatley following collection, mix sample by gently inverting 5 times

1. Allow sample to clot for a minimum of 30 minutes
2. Spin within two (2) hours of sample collection

Gold serum separator (SST) tube

Red serum vial/tube, 5 mL

1. Allow sample to clot
2. Spin within two (2) hours of sample collection
3. Transfer serum to a Transfer vial/tube with cap - 12mL (LabCorp), labelled as serum

Transfer vial/tube with cap - 12mL (LabCorp)

Refrigerated

• Bacterial contamination
• Hemolysis
•  Lipemia

Atypical ANCA: Indirect fluorescent antibody (IFA)

Saccharomyces cerevisiae, IgA and IgG: Enzyme immunoassay (EIA)

Saccharomyces cerevisiae,IgA                                             

Negative: <20.0
Equivocal:    20.1 - 24.9
Positive:   ≥ 25.0

Saccharomyces cerevisiae, IgG

Negative: <20.0
Equivocal:    20.1 - 24.9
Positive:   ≥ 25.0

Atypical pANCA                     

Negative: < 1:20

IgA and IgG antibody testing for S. cerevisiae is useful adjunct testing for differentiating Crohn's disease and ulcerative colitis.  Nearly 80% of Crohn's disease patients are positive for either IgA or IgG.  In ulcerative colitis, less than 15% are positive for IgG, and less than 2% are positive for IgA.  Fewer than 5% of healthy controls are positive for either IgG or IgA antibody, and no healthy controls had antibody for both.  The atypical ANCA pattern has been observed in a significant percentage of patients with ulcerative colitis, primary sclerosing cholangitis, and autoimmune hepatitis.